Scor­ing the 5 top phase III drugs in the glob­al pipeline

Here at End­points we all agree: we love lists about the most valu­able drugs in drug­mak­ers pipeline. And that reg­u­lar­ly brings us back to the an­a­lysts at EP Van­tage.


Their phase III list is dom­i­nat­ed by Roche, which is pulling off a string of block­buster ap­provals. Re­gen­eron and Sanofi, per­haps the best part­ners in biotech, have a clear shot with dupilum­ab. Lil­ly, which has be­gun to rack up bad­ly need­ed suc­cess­es in Phase III, is ex­pect­ed to score with abe­maci­clib (though CDK 4/6 will be com­pet­i­tive).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.